Non-alcoholic Fatty Liver Disease: all 1,507 studies

Page 15 of 16. Open to participants first (303), then studies with results posted, then the rest; newest registration first within each.

• Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver DiseaseCompletedNCT01446276Not applicable
• Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT01418027Phase 3
• Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASHTerminatedNCT01406704Phase 4
• Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 DiabetesCompletedNCT01399645Phase 2
• Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic SteatohepatitisWithdrawnNCT01384578Phase 3
• Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver DiseaseCompletedNCT01373554Phase 2
• Effect of Dietary Macronutrient CompositionCompletedNCT01371396Not applicable
• Meta-analyses of Fructose and Cardiometabolic RiskStatus unknownNCT01363791
• Dietary Protein and Hepatic Fat AccumulationCompletedNCT01354626Not applicable
• Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver DiseaseCompletedNCT01327443Not applicable
• Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic SteatohepatitisCompletedNCT01324414
• Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!CompletedNCT01317576Not applicable
• Association Between Non-alcoholic Fatty Liver Disease and Iron StatusStatus unknownNCT01307254
• Effect of Fructose Reduction on Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome in Overweight ChildrenStatus unknownNCT01306396Not applicable
• Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary AtherosclerosisStatus unknownNCT01282892
• Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath TestStatus unknownNCT01281059Not applicable
• Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical TrialWithdrawnNCT01279434Not applicable
• The Impact of Deferasirox on Non-Alcoholic-SteatohepatitisCompletedNCT01278056Phase 1/2
• The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver DiseaseCompletedNCT01277237Phase 3
• A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver DiseaseCompletedNCT01277094Phase 1
• The Role of Resistance Training in Non Alcoholic Fatty Liver DiseaseCompletedNCT01264198Not applicable
• Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose ProductionCompletedNCT01262326Not applicable
• Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 DiabetesTerminatedNCT01260246Not applicable
• Selenoprotein P and Non-alcoholic Fatty Liver DiseaseCompletedNCT01257685
• Liraglutide Efficacy and Action in Non-Alcoholic SteatohepatitisCompletedNCT01237119Phase 2
• Trial of Hepaguard® in Adults With Nonalcoholic SteatohepatitisCompletedNCT01210989Not applicable
• Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT01208649Phase 4
• Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic SyndromeCompletedNCT01205087Phase 2
• Effects of Dietary Fructose Reduction in Children With Hepatic SteatosisCompletedNCT01188083Not applicable
• A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT01167088Phase 2
• Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver DiseaseCompletedNCT01147523Phase 2
• The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver DiseaseStatus unknownNCT01139632
• Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)CompletedNCT01110577
• Role of Immune System in Obesity-related Inflammation and Cardiometabolic RiskCompletedNCT01104220Not applicable
• Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver BiopsyCompletedNCT01100398
• Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic SteatohepatitisCompletedNCT01094158Phase 2
• Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver DiseaseCompletedNCT01084486Phase 1/2
• Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)Status unknownNCT01083992Not applicable
• The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic SteatohepatitisCompletedNCT01068444Phase 2
• Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)CompletedNCT01056133Phase 2
• Anti-Fibrotic Effects of Losartan In Nash Evaluation StudyCompletedNCT01051219Phase 3
• The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 DiabetesActive, not recruitingNCT01047735Not applicable
• Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2CompletedNCT01030484
• Bovine Colostrum for Patients With Non Alcoholic Fatty Liver DiseaseCompletedNCT01016418Phase 1/2
• Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass SurgeryCompletedNCT01007955
• The Effect of Protandim on Non-alcoholic SteatohepatitisCompletedNCT00977730Not applicable
• Regulation of FGF21 by Nutritional ChallengesCompletedNCT00968747Not applicable
• Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver DiseaseStatus unknownNCT00941642Phase 4
• A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With PsoriasisCompletedNCT00930384
• Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected PersonsCompletedNCT00889577
• Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery CandidatesCompletedNCT00887393Not applicable
• Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT00885313Phase 1/2
• Effect of Dietary and Life Style Modification on Post Liver Transplant ObesityTerminatedNCT00878592Not applicable
• A Pilot Study on Whey Protein Supplementation in Non Alcoholic Fatty Liver DiseaseCompletedNCT00870077Not applicable
• Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and PrebioticsCompletedNCT00870012Not applicable
• Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver DiseaseCompletedNCT00868933Not applicable
• Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese WomenCompletedNCT00862433Phase 1
• Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy VolunteersCompletedNCT00856869Phase 1/2
• Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese PatientsStatus unknownNCT00844779
• Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) InfectionStatus unknownNCT00842205Not applicable
• Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for OverweightCompletedNCT00823277
• Efficacy and Safety of Diamel in Patients With Nonalcoholic SteatohepatitisCompletedNCT00820651Phase 3
• The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver DiseaseCompletedNCT00819338Phase 2
• Safety and Efficacy of Hoodia Gordonii for Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT00816465Phase 1
• Evaluation of Intestinal Microbiome in Obese KidsWithdrawnNCT00816296
• Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver DiseaseCompletedNCT00815009Not applicable
• The Effect of Probiotics on Non Alcoholic Fatty Liver DiseaseTerminatedNCT00808990Phase 1
• PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT00794716Phase 2
• Exercise Dose and Nonalcoholic Fatty Liver DiseaseCompletedNCT00771108Not applicable
• Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT00740610Phase 2
• Fatty Liver and Obstructive Sleep ApneaCompletedNCT00730873Not applicable
• De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver DiseaseCompletedNCT00714129Not applicable
• Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASHCompletedNCT00706537Phase 1
• Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)Status unknownNCT00699036Phase 2
• Study of Fish Oil to Reduce ALT Levels in AdolescentsTerminatedNCT00694746Phase 1
• Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)CompletedNCT00681408Phase 2/3
• A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT00677521Phase 2
• Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in ChildrenWithdrawnNCT00677183
• A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831CompletedNCT00668070Phase 2
• Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT00666016Phase 2
• Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron StoresStatus unknownNCT00658164Phase 3
• Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT00655018Phase 2/3
• Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver DiseaseCompletedNCT00641524Not applicable
• Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control StudyTerminatedNCT00637520
• Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver DiseaseCompletedNCT00633282Phase 2
• Betaine in Patients With Nonalcoholic SteatohepatitisCompletedNCT00586911Phase 2
• Effects of Alanine in Patients With Nonalcoholic SteatohepatitisCompletedNCT00586885Not applicable
• The Role of Leptin Receptors in NASHCompletedNCT00583999
• An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 DiabetesTerminatedNCT00577148Phase 3
• Non Alcoholic Fatty Liver Disease (NAFLD) in Hong KongStatus unknownNCT00577044
• An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without DiabetesTerminatedNCT00576667Phase 3
• Efficacy and Safety of Viusid in Patients With Nonalcoholic SteatohepatitisCompletedNCT00509418Phase 3
• A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic SteatohepatitisCompletedNCT00492700Phase 2
• Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic SteatohepatitisCompletedNCT00470171Phase 2
• Phase I Trial of Silymarin for Chronic Liver DiseasesCompletedNCT00389376Phase 1
• Non Alcoholic Fatty Liver Disease Influence of Statin TherapyWithdrawnNCT00375349Not applicable
• Metformin in Non-Alcoholic Fatty Liver DiseaseStatus unknownNCT00303537Phase 2/3
• Weight Management in Nonalcoholic SteatohepatitisCompletedNCT00266019Phase 2
• Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)Status unknownNCT00247117Not applicable
• Effect of Omega-3 PUFA Supplementation in NAFLD PatientsCompletedNCT00230113Not applicable

← Non-alcoholic Fatty Liver Disease overview